Condition: Pancreatic Ductal Adenocarcinoma · Sponsor: University of Pennsylvania
Phase II, open-label, single-arm study of CD40/Dectin-1 immunotherapy as maintenance treatment in patients with unresectable pancreatic ductal adenocarcinoma (PDA) who have not progressed following 4-8 months of first line (1L) chemotherapy.
This description comes directly from the study's public registry record.
Abramson Cancer Center Clinical Trials Service · 215-349-8245 · PMCancerResearch@pennmedicine.upenn.edu
Always discuss trial participation with your own doctor first.
| Hospital of the University of Pennsylvania | Philadelphia, Pennsylvania, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07199764